Tracleer and PPH News
PR Pharmaceuticals Files IND for Pulmonary Hypertension
FORT COLLINS, Colo., Dec. 20 /PRNewswire/ -- PR Pharmaceuticals, Inc. (PRP), announced today that it filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the Company's first clinical product, PulmoLAR(TM) (2-methoxyestradiol) for the treatment of pulmonary arterial hypertension (PAH).
"This IND for PulmoLAR is a milestone for our company and an important step in our development of this novel therapy. The data that have and continue to be generated in animal models of PAH and other cardiovascular injury lend strong support to this development initiative. Recently, we've generated a considerable body of important safety information that encourage us to begin human studies with our proprietary low-volume, sustained-release injectable formulation," said Dr. Claude Piche, PRP's Vice President of Clinical Development and Regulatory Affairs.
Stevan P. Tofovic, M.D., Ph.D., Assistant Professor at the University of Pittsburgh School of Medicine and principal investigator on the use of PulmoLAR in animal models of PAH, stated, "Our work in numerous animal models of cardiovascular injury, and in models of PAH in particular, indicates treatment with PulmoLAR has a dramatic effect in improving survival, reducing the damage to the arteries of the lungs and preventing subsequent right heart failure. We've also shown reduced injury and significant improvements in survival in a recently completed study in an animal model of PAH in which we compared 2-methoxyestradiol to some of the leading drugs used to treat PAH in humans. These results are very encouraging and we are excited to see PulmoLAR progress to clinical testing."
About PulmoLAR(TM)
The active ingredient in PulmoLAR is 2-methoxyestradiol (2ME), an endogenous, non-estrogenic metabolite of estradiol. 2ME has multiple mechanisms of action, many of which are particularly relevant to PAH. In vitro studies have demonstrated 2ME reduces endothelial cell production of endothelin-1 and increases synthesis of prostacyclin. 2ME is also a potent antiproliferative agent. PulmoLAR is PRP's proprietary, sustained-release, injectable formulation. Animal studies conducted to date suggest a single, low-volume injection may provide therapeutic levels of drug for one month or more. In April 2005, Orphan Drug Status designation was granted by the FDA for use of PulmoLAR for the treatment of pulmonary arterial hypertension.
About PR Pharmaceuticals, Inc.
PR Pharmaceuticals, Inc. (PRP) is a privately held biopharmaceutical company focused on developing, manufacturing and commercializing bioactive compounds in sustained-release formulations. The Company specializes in injectable, biodegradable formulations and has a significant intellectual property position in the encapsulation of large molecules such as proteins and peptides as well as encapsulation of classic small molecules into biodegradable microparticles. PRP is applying compelling and patented technology to create a diverse range of candidate pharmaceutical products to address unmet medical needs.
PulmoLAR(TM) is a trademark of PR Pharmaceuticals, Inc.
----------------------------------------------------------
Source: PR Pharmaceuticals, Inc.
Mesothelioma Search Engine to Consolidate Medical and Legal Information
New lung cancer search engine provides information on medical and legal web sites for those researching this asbestos-caused killer cancer
Minneapolis, MN, February 25, 2006 --(PR.COM)-- On the one-year anniversary of the launch of their Vioxx Search Engine, Nielsen Technical Services today announced the launch of their Mesothelioma Search Engine.
Niche search engines or vertical search engines have increased in popularity, but the time and expense of creating and maintaining a search engine for a highly vertical segment of an available search audience is generally not a good investment financially. When asked about the financial viability of such a site, owner Chris Nielsen said, “We have some interested parties that would like to be associated with us and are exploring those options, but will not compromise our values for the sake of making a buck. The massive amount of money the asbestos and mesothelioma lawyers are spending have resulted in a feeding frenzy which has spawned thousands of sites and millions of pages of fluff, trash, and recycled content. I admit our site is expected to carry ads at some point, but that is not the reason for creating the site.”
Nielsen was then asked the reason for creating such a site. “I just could not find a central source to go for information where sites were not bidding or competitively optimizing for position and search engine ranking. Search engines are fighting to maintain relevancy but they are having problems. Many ‘scraper sites’ are only looking to get visitors that will click on ads to reach real content. If you try a search for ‘mesothelioma’ it should be clear what the problem is.”
As with their Vioxx medical and legal search engine, Mesothelioma Search Engine will carry no paid search engine results or paid inclusion of sites. The site has a form for visitors to suggest sites. The list of sites included in the index is posted on the site and available for download, a feature not offered by other search engines.
The company is indexing selected sites for those looking for more information such as patients, researchers, families, doctors, pharmacists, students, and those in the legal profession. This site is offered as a public service for those looking for information related to medical and legal information on mesothelioma lung cancer, or asbestos lung cancer for which there is no cure and is caused by exposure to asbestos fibers or asbestos dust.
About Nielsen Technical Services
The company is based in Minneapolis, Minnesota and has been providing computer and software services since 1988. The Internet has transformed the company from a hardware services company into Internet consulting and specializes in search engine optimization.
Contact:
Chris Nielsen
Mesothelioma Search Engine
952-943-0170
webmaster@Mesothelioma-Search-Engine.com
|
